Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes

HIV Clinical Trials

Volumn 3, Issue 5, 2002, Pages 403-411

  Holguín, Africa ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiretroviral therapy; Drug resistance; Genetic variability; HIV subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; FOSCARNET; LAMIVUDINE; NEVIRAPINE; RITONAVIR; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS RESISTANCE;

EID: 0036750078     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/7bwp-0x7f-nxna-qrnp     Document Type: Article

References (90)

1. Coffin J. HIV population dynamic in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
2. Peeters M. Recombinant HIV sequences: their role in the global epidemic. In: Kuiken C, Foley B, Hahn B, et al., eds. HIV Sequence Compendium. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2000:54-72.
3. Robertson D, Anderson J, Bradac J, et al. HIV-1 nomenclature proposal. Science. 2000;288:55-56.
4. Kuiken C, Foley B, Hahn B, et al. HIV Sequence Compendium. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2000.
5. Delgado E, Thompson M, Villahermosa M, et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J AIDS. 2002;29:536-543.
6. Quiñones-Mateu, Arts E. Recombination in HIV-1: update and implications. AIDS Rev. 1999;1:89-100.
7. Blackard J, Cohen D, Mayer K. HIV superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis. 2002;34:1108-1114.
8. Holguín A, Rodés B, Soriano V. Protease gene analysis of HIV type 1 non-B subtypes in Spain. AIDS Res Hum Retroviruses. 2000;16:1395-1403.
9. Holguín A, Rodés B, Soriano V. Recombinant HIV type 1 circulating in Spain. AIDS Res Hum Retroviruses. 2000;16:505-511.
10. Holguin A, Alvarez A, Soriano V. Heterogeneous nature of HIV-1 subtype G recombinants spreading in Southern Europe. J Virol. In press.
11. Alaeus A, Leitner T, Lidman K, Albert J. Most HIV-1 genetic subtypes have entered Sweden. AIDS. 1997;11:199-202.
12. Barlow K, Tatt I, Cane P, Pillay D, Clewley J. Recombinant strains of HIV type 1 in the United Kingdom. AIDS Res Hum Retroviruses. 2001;17:467-474.
13. Op de Coul E, Coutinho R, van der Schoot A, et al. The impact of immigration on env HIV-1 subtype distribution among heterosexuals in the Netherlands: influx of subtype B and non-B strains. AIDS. 2001;15:2277-2286.
14. Couturier E, Damond F, Roques P, et al. HIV-1 diversity in France, 1996-1998. AIDS. 2000;14:289-296.
15. Böni J, Pyra H, Gebhardt M, et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr. 1999;22:174-179.
16. Holguín A, Álvarez A, Soriano V. High prevalence of subtype G and spectrum of natural polymorphisms at the protease gene among HIV-infected immigrants attended in Madrid. AIDS. In press.
17. Apetrei C, Loussert-Ajaka I, Descamps D, et al. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS. 1996;10:F57-F60.
18. Baldrich-Rubio E, Anagonou S, Stirrups K, et al. A complex HIV type 1 A/G/J recombinant virus isolated from a seronegative patient with AIDS from Benin, West Africa. J Gen Virol. 2001;82:1095-1106.
19. Candotti D, Adu-Sarkodie Y, Davies F, et al. AIDS in an HIV-seronegative Ghanaian woman with intersubtype A/G recombinant HIV-1 infection. J Med Virol. 2000;62:1-8.
20. Holguín A, de Mendoza C, Soriano V. Comparison of three commercial methods for quantification of plasma viraemia in clinical specimens belonging to non-B subtypes. Eur J Clin Microbiol Infect Dis. 1999;18:256-259.
21. Jenny-Avital E, Beatrice S. Erroneously low or undetectable plasma HIV-1 RNA load, determined by PCR, in West African and American patients with non-B subtype HIV-1 infection. Clin Infect Dis. 2001;32:1227-1230.
22. Descamps D, Apetrei C, Collin G, et al. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS. 1998;12:1109-1111.
23. Shafer R, Eisen J, Merigan T, Katzenstein D. Sequence and drug susceptibility of subtype C reverse transcriptase from HIV-1 seroconverters in Zimbabwe. J Virol. 1997;71:5441-5448.
24. Hirsch M, Conway B, D'Aquila R, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA panel. JAMA. 1998;279:1984-1991.
25. Vandamme A, Van Laethem K, de Clerq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs. 1999;57:337-361.
26. Schinazi R, Larder B, Mellors J. Mutations in retroviral genes associated with drug resistance: 1999-2000 update. Int Antiviral News. 2001;7:46-69.
27. Erickson J, Gulnik S, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS. 1999;13(suppl A):S189-S204.
28. Quiñones-Mateu M, Weber J, Rangel H, Chakraborty B. HIV-1 fitness and antiretroviral drug resistance. AIDS Rev. 2001;3:223-242.
29. Martínez-Picado J, Savara A, Sutton L, D'Aquila R. Replicative fitness of protease inhibitor resistant mutants of HIV-1. J Virol. 1999;73:3744-3752.
30. Shafer R, Dupnik K, Winters M, Eshleman S. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. In: Kuiken C, Foley B, Hahn B, et al., eds. HIV Sequence Compendium. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2000.
31. Schmit C, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 1996;10:995-999.
32. Eastman P, Mittler J, Kelso R, et al. Genotypic changes in HIV-1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir monotherapy. J Virol. 1998;72:5154-5164.
33. Robert N, Craig J, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS. 1998;12:453-460.
34. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of HIV-1 variants with high-level resistance to protease inhibitors. J Virol. 1997;71:1089-1096.
35. Miller V. International perspectives on antiretroviral resistance, Resistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001;26(suppl 1):34-50.
36. Mammano F, Petit C, Clavel F. Resistance-associated loss fitness in HIV virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor treated patients. J Virol. 1998;72:7632-7637.
37. Borman A, Paulous S, Clavel F. Resistance to HIV-1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol. 1996;77:419-426.
38. Rose R, Gong Y, Greytok J, et al. HIV-1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA. 1996:93:1648-1653.
39. Nijhuis M, Boucher C, Schipper P, et al. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA. 1998;95:14441-14446.
40. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in HIV-1 resistance to protease inhibitors. J Virol. 1999;70:3763-3769.
41. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol. 2000;49:41-66.
42. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis. 2001;14:23-28.
43. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and gagpol processing defects in HIV-1 variants selected for resistance to protease inhibitors in vivo. J Virol. 1998;72:3300-3306.
44. Nájera I, Holguín A, Quiñones-Mateu M, et al. Pol gene quasispecies of HIV: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995;69:23-31.
45. Lech W, Wang G, Li Yan Y, et al. In vivo sequence diversity of the protease of HIV-1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol. 1996;70:2038-2043.
46. Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001;26(suppl 1):34-50.
47. Frater A, Beardall A, Ariyoshi K, et al. Impact of the polymorphism in RT and protease on outcome of highly active antiretroviral therapy in HIV-1 infected African patients. AIDS. 2001;15:1493-1502.
48. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods. 2001;94:45-54.
49. Yahi N, Fantini J, Tourres C, et al. Use of drug resistance sequence data for the systematic detection of non-B HIV-1 subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J infect Dis. 2001;183:1311-1317.
50. Balotta C, Facci G, Violin M, et al. Increasing prevalence of non-B clade HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J AIDS. 2001;27:499-505.
51. Janssens W, Buvé A, Nkengasong J. The puzzle of HIV-1 subtypes in Africa. AIDS. 1997;11:705-712.
52. Laurent C, Delaporte E. Epidemiology of HIV infection in sub-Saharan Africa. AIDS Rev. 2001;3:59-66.
53. Holguín A, Álvarez A, Soriano V. The Canary Islands (Spain) as a key entrance for HIV-1 non-B subtypes in Southern Europe. Clin Infect Dis. In press.
54. Pieniazek D, Rayfield M, Hu D, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease-naive individuals worldwide. AIDS. 2000;14:1489-1495.
55. Vergne L, Peeters M, Mpoundi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-B HIV type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38:3919-3925.
56. Becker-Pergola G, Kataaha P, Johnston-Dow L, et al. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan Adults. AIDS Res Hum Retroviruses. 2000;16:807-813.
57. Tanuri A, Vicente A, Otsuki K, et al. Genetic variation and susceptibilities to protease inhibitors among subtypes B and F isolates in Brazil. Antimicrob Agents Chemother. 1999;43:253-258.
58. Grossman Z, Vardinon N, Chemtob D, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453-1460.
59. Cane P, de Ruiter A, Rice P, et al. Resistance-associated mutations in the HIV-1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microb. 2001;39:2652-2654.
60. Pérez-Álvarez L, Cuevas T, Villahermosa L, et al. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of HIV-1 in infected individuals in Spain (Galicia). J Hum Virol. 2001;4:35-38.
61. Luk KC, Kaptue L, Zekeng, et al. Natural occurring sequence polymorphisms within HIV type 1 group O protease. AIDS Res Hum Retroviruses. 2001;16:1555-1561.
62. Nuñez M, Gallego O, González de Requena D, et al. Emergence of resistance to nelfinavir in HIV-infected subjects experiencing early virological failure. Int J Antimicrob Therapy. In press.
63. Gomes P, Diogo I, Goncalves F, et al. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, Washington. Abstract 46.
64. Grossman Z, Maayan S, Averbuck D, et al. Longitudinal analysis of RT and protease mutations in HIV subtype C patients receiving antiretroviral therapy. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, Washington. Abstract 565.
65. Soriano V. Sequencing antiretroviral drugs. AIDS. 2001;15:547-551.
66. Quiñones-Mateu M, Albright J, Mas A, Soriano V, Arts E. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with HIV-1 group O strains. J Virol. 1998;72:9002-9015.
67. De Baar M, Janssens W, De Ronde A, et al. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res Hum Retroviruses. 2000;14:1385-1394.
68. Schmidt B, Walter H, Moschik B, et al. Simple algorithm derived from a geno/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS. 2000;14:1731-1738.
69. Clark N, Dieng Sarr A, Sankale J, et al. Immunological and virologic response of HIV-2 infection to antiretroviral therapy. AIDS. 1998;12:2506-2507.
70. Rodés B, Holguín A, Soriano V, et al. Emergence of drug resistance mutations in HIV-2-infected subjects undergoing antiretroviral therapy. J Clin Microb. 2000;38:1370-1374.
71. Van Rompey K, Breenier J, Marthas M, et al. A zidovudine resistant SIV mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother. 1997;41:278-283.
72. Dunne A, Mitchell F, Coberly S, et al. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS. 2001;15:1471-1475.
73. Kellam P, Larder B. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of HIV-1 isolates. Antimicrob Agents Chemother. 1994;38:23-30.
74. Hertogs K, Conant M, Schel P, et al. The RT-Antivirogram™: a rapid and accurate method to determine phenotype (multi-) drug resistance in plasma of patients treated with various HIV-1 RT inhibitors. Antivir Ther. 1996;1:40.
75. Walter H, Schmidt B, Korn K, et al. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol. 1999;13:71-80.
76. Martínez-Picado J, Sutton L, De Pascale M, Savara A, D'Aquila R. HIV-1 cloning vectors for antiretroviral resistance testing. J Clin Microbiol. 1999;37:2943-2951.
77. Petropoulos C, Parkin N, Limoli K, et al. A novel phenotypic drug susceptibility assay for HIV-1. Antimicrob Agents Chemother. 2000;44:920-928.
78. Holguín A, Hertogs K, Soriano V. Performance of VIRCO drug resistance assays testing HIV-1 non-B subtypes. Clin Microb Infect. In press.
79. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E HIV-1 primary isolates. AIDS Res Hum Retroviruses. 1998;14:157-162.
80. Apetrei C, Descamps D, Collin G, et al. HIV-1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol. 1998;72:3534-3538.
81. Hermans P, Schmit J, Kabeya K, et al. Virological response to salvage therapy at 6 months in patients with B and non-B subtypes. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, Washington. Abstract 427.
82. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS. 1999;13:F17-F21.
83. Perno C, Cozzi-Lepri A, Balotta, et al. Secondary mutations in the protease region of HIV and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis. 2001;184:983-991.
84. Perez E, Rose E, Peyser B, et al. HIV-1 protease genotype predicts immune and viral response to combination therapy with protease inhibitors (Pls) in PI-naive patients. J Infect Dis. 2001;183:579-588.
85. Isaacson I, Kempf D, Calvez V, et al. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, Washington. Abstract 559.
86. Rodes B, Holguin A, Soriano V, et al. Emergence of drug resistance mutations in HIV-2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol. 2000;38:1370-1374.
87. Yamaguchi J, Vallari A, Swanson P, et al. Evaluation of HIV-1 group O isolates: identification of five phylogenetic clusters. AIDS Res Hum Retroviruses. 2002;18:269-282.
88. Gao F, Yue L, Robertson D, et al. Genetic diversity of HIV type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994;68:7433-7447.
89. Chen Z, Luckay A, Sodora D, et al. HIV-2 seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol. 1997;71:3953-3960.
90. Yamaguchi J, Devare S, Brennan C. Identification of a new HIV-2 based on phylogenetic analysis of full-length genomic sequence. AIDS Res Hum Retroviruses. 2000;16:925-930.